Canopy Growth (CGC) Other Non-Current Assets (2017 - 2026)
Canopy Growth (CGC) reported Other Non-Current Assets of $12.2 million for Q1 2026, up 6.43% on a YoY basis from $11.4 million in Q1 2025, and down 95.77% sequentially from $287.4 million in Q4 2025.
Canopy Growth (CGC) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Other Non-Current Assets data on file, last reported at $12.2 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 6.43% year-over-year to $12.2 million; the trailing twelve-month figure through Mar 2026 stood at $12.2 million (up 6.43% YoY), and the FY2026 full-year result was $12.2 million, up 6.43% from the prior year.
- Other Non-Current Assets slipped to $12.2 million in Q1 2026, from $287.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $359.0 million in Q4 2024 to a low of $4.8 million in Q4 2022.
- A 5-year average of $49.7 million and a median of $12.2 million in 2025 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets plunged 60.51% in 2022 and jumped 1827.17% in 2024, its largest moves.
- Tracing CGC's Other Non-Current Assets over 5 years: stood at $4.8 million in 2022, then soared by 291.34% to $18.6 million in 2023, then jumped by 1827.17% to $359.0 million in 2024, then declined by 19.95% to $287.4 million in 2025, then sank by 95.77% to $12.2 million in 2026.
- Business Quant data shows CGC's Other Non-Current Assets at $12.2 million in Q1 2026, $287.4 million in Q4 2025, and $12.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - | 12.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.15 Mn |
| Dec 31, 2025 | 287.36 Mn |
| Sep 30, 2025 | 12.17 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Mar 31, 2025 | 11.42 Mn |
| Dec 31, 2024 | 358.98 Mn |
| Sep 30, 2024 | 13.99 Mn |
| Jun 30, 2024 | 16.49 Mn |
| Mar 31, 2024 | 5.97 Mn |
| Dec 31, 2023 | 18.63 Mn |
| Sep 30, 2023 | 26.51 Mn |
| Jun 30, 2023 | 14.52 Mn |
| Mar 31, 2023 | 14.79 Mn |
| Dec 31, 2022 | 4.76 Mn |
| Sep 30, 2022 | 11.12 Mn |
| Jun 30, 2022 | 11.34 Mn |
| Mar 31, 2022 | 12.11 Mn |
| Dec 31, 2021 | 12.05 Mn |
| Sep 30, 2021 | 7.12 Mn |
| Jun 30, 2021 | 7.74 Mn |